Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
The SURMOUNT trials show consistently greater weight loss with tirzepatide compared to semaglutide, but also steeper regain after discontinuation
Buyer Takeaway: Confirm the ingredient list from the physical product label
10% off at Baltic Peptides Apply this code at checkout (final step): SKU: BBL-42-10mg Checkout: Current partner listing and availability Alternative Research Intensities *Independent research variants for specific volumetric study parameters
Workforce Our Workforce Collection provides access to the latest insights from Aons Human Capital team on topics ranging from health and benefits, retirement and talent practices
Research from the STEP trials (semaglutide) and SURMOUNT-4 (tirzepatide) shows that without ongoing pharmacotherapy or substantial behavioral interventions, significant weight regain occurs within the first year after stopping treatment
